UNASSIGNED: The results from molecular assays can be affected significantly by the preanalytic condition of cytologic samples. The authors review current knowledge on the use of cytologic samples for @entity470 ( @entity470 ) mutation testing in @entity1149 with a focus on preanalytic parameters. A systematic electronic search of the MEDLINE database was performed to identify original articles that reported the use of cytologic samples for @entity470 molecular analysis and included a minimum of 100 samples. The information collected included author(s), journal, and year of publication; number of @entity1 and samples; sampling method; type of preparation; type of fixative; staining techniques; mutation analysis techniques; @entity5 cellularity; the percentage of @entity5 cells; data on DNA quantity, quality, and concentration; failed assays; and the mutation rate. @entity470 mutation analysis was conducted on 4999 cytologic samples from 22 studies that fulfilled the inclusion criteria. Fine-needle aspirates and @entity1143 were the most common types of specimens used. DNA was mainly extracted from cell blocks and smears, and the most commonly reported fixatives included @entity406 , @entity1068 , and CytoLyt. Cellularity assessments and DNA yields were available from 5 studies each. The average success rate for the assays that used cytologic specimens was 95.87% (range, 85.2%-100%). The mutation rate ranged from 6% to 50.46%, and a higher mutation detection rate and lower numbers of insufficient cases were reported for @entity1143 and lymph node samples from endobronchial ultrasound-guided transbronchial needle aspiration compared with histologic specimens. Low cellularity and a low percentage of @entity5 cells were associated with higher test failure rates. Future guidelines should consider the current data for specific recommendations regarding cytologic samples. @entity5 ( @entity5 Cytopathol) 2015.    2015 The Authors. @entity5 Cytopathology published by Wiley Periodicals, Inc. on behalf of American @entity5 Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Preanalytic parameters in XXXX mutation testing for @entity1149 : A review of cytologic series.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusions'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Cancer'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer'] @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin'] @entity1068 :: ('MESH:D000431', 'Chemical') :: ['ethanol']
@entity470 :: (1956,Gene) :: ['epidermal growth factor receptor']
